Banco Bradesco S A (Put) (BBD) Stock Value Declined While Parallax Volatility Advisers LP Has Boosted by $3.74 Million Its Holding; Ligand Pharmaceuticals (LGND) Holder Cardinal Capital Management Decreased Stake by $35.48 Million

June 15, 2018 - By whatsonthorold

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Logo

Parallax Volatility Advisers Lp increased its stake in Banco Bradesco S A (Put) (BBD) by 755.56% based on its latest 2018Q1 regulatory filing with the SEC. Parallax Volatility Advisers Lp bought 340,000 shares as the company’s stock declined 26.72% with the market. The institutional investor held 385,000 shares of the major banks company at the end of 2018Q1, valued at $4.57M, up from 45,000 at the end of the previous reported quarter. Parallax Volatility Advisers Lp who had been investing in Banco Bradesco S A (Put) for a number of months, seems to be bullish on the $41.37 billion market cap company. The stock increased 0.07% or $0.005 during the last trading session, reaching $6.695. About 10.89 million shares traded or 1.37% up from the average. Banco Bradesco S.A. (NYSE:BBD) has risen 14.13% since June 15, 2017 and is uptrending. It has outperformed by 1.56% the S&P500. Some Historical BBD News: 26/04/2018 – BRAZIL’S BANCO BRADESCO SAYS LOAN-LOSS PROVISIONS MAY END 2018 AT THE BOTTOM OF THE ESTIMATED RANGE; 26/04/2018 – Banco Bradesco 1Q Net BRL5.1B; 04/04/2018 – BRADESCO CEO SEES LITTLE IMPACT FROM CHANGE IN DEBIT CARD FEES; 10/05/2018 – Creditors lead the efforts to sell Brazil’s Odebrecht rail unit; 05/04/2018 – MUFG SELLS PART OF ITS STAKE IN BANCO BRADESCO FOR 45.3B YEN; 26/04/2018 – BRAZIL’S BANCO BRADESCO CEO SAYS BANK IS EAGER TO GROW ITS LOAN BOOK; 27/03/2018 – Bradesco names new CEO for insurance arm from asset management division; 10/04/2018 – Brazilian banks will offer alternatives to overdraft credit; 09/05/2018 – Moody’s assigns provisional ratings to shares of Chemical X – FIDC lndústria Petroquí; 09/03/2018 BRADESCO SEES BRAZIL’S SELIC CUT TO 6.5% IN MARCH

Cardinal Capital Management Llc decreased its stake in Ligand Pharmaceuticals Inc (LGND) by 32.86% based on its latest 2018Q1 regulatory filing with the SEC. Cardinal Capital Management Llc sold 215,011 shares as the company’s stock rose 24.00% while stock markets declined. The institutional investor held 439,335 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $72.56 million, down from 654,346 at the end of the previous reported quarter. Cardinal Capital Management Llc who had been investing in Ligand Pharmaceuticals Inc for a number of months, seems to be less bullish one the $4.11 billion market cap company. The stock increased 0.26% or $0.5 during the last trading session, reaching $192.59. About 157,163 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 66.74% since June 15, 2017 and is uptrending. It has outperformed by 54.17% the S&P500. Some Historical LGND News: 22/03/2018 – LIGAND PHARMACEUTICALS, RETROPHIN AMEND SUBLICENSE PACT; 07/03/2018 – LIGAND PHARMACEUTICALS SAYS UNDERREPORTED POTENTIAL AGGREGATE MILESTONE PAYMENTS RELATED TO LICENSE AGREEMENT WITH ROIVANT SCIENCES FOR LGD-6972; 10/05/2018 – Ligand Pharmaceuticals: Under Pact, KSQ Will Be Able to Use Ligand’s Full OmniAb Platform to Discover Antibodies; 03/05/2018 – Ligand Pharma Company Marketing Set By Stephens Inc for May. 10; 20/03/2018 – SPARK’S LUXTURNA GETS FIRST COMMERCIAL USE 3 MOS AFTER FDA OK; 21/04/2018 – DJ Ligand Pharmaceuticals Incorporated, Inst Holders, 1Q 2018 (LGND); 05/03/2018 Ligand to Participate in Two Upcoming Investor Conferences; 24/04/2018 – Ligand Pharma Closes Below 50-Day Moving Average: Technicals; 23/05/2018 – BMS-986231 (Bristol-Myers Squibb/Ligand) Drug Overview 2018: A Second-Generation Prodrug That Chemically Breaks Down to Produce Nitroxyl (HNO) and an lnactive Byproduct – ResearchAndMarkets.com; 06/03/2018 – LIGAND TO GET UPFRONT LICENSE FEES, ELIGIBLE FOR MILESTONE

Among 7 analysts covering Banco Bradesco SA (NYSE:BBD), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Banco Bradesco SA had 12 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, January 18 by Citigroup. As per Monday, September 11, the company rating was upgraded by Goldman Sachs. The stock of Banco Bradesco S.A. (NYSE:BBD) has “Buy” rating given on Monday, October 12 by Deutsche Bank. J.P. Morgan upgraded it to “Buy” rating and $13.0 target in Monday, January 22 report. The firm has “Neutral” rating by Goldman Sachs given on Monday, May 2. As per Tuesday, March 22, the company rating was downgraded by Deutsche Bank. The stock has “Buy” rating by Bank of America on Monday, March 14. The company was maintained on Wednesday, September 21 by Goldman Sachs. On Wednesday, April 12 the stock rating was upgraded by Scotia Capital to “Sector Perform”. Citigroup downgraded Banco Bradesco S.A. (NYSE:BBD) on Friday, April 8 to “Sell” rating.

Parallax Volatility Advisers Lp, which manages about $4.50B and $74.37B US Long portfolio, decreased its stake in Mgic Invt Corp Wis (NYSE:MTG) by 56,635 shares to 4,239 shares, valued at $55,000 in 2018Q1, according to the filing. It also reduced its holding in Las Vegas Sands Corp (Call) (NYSE:LVS) by 578,100 shares in the quarter, leaving it with 492,500 shares, and cut its stake in Sanderson Farms Inc (NASDAQ:SAFM).

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on August, 6. They expect $0.78 EPS, up 44.44% or $0.24 from last year’s $0.54 per share. LGND’s profit will be $16.63M for 61.73 P/E if the $0.78 EPS becomes a reality. After $1.38 actual EPS reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -43.48% negative EPS growth.

More recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: Seekingalpha.com which released: “Xeris Pharmaceuticals on deck for IPO” on May 25, 2018. Also Investorplace.com published the news titled: “3 Biotech Stocks Up in the Past Month on Industry Turnaround” on June 07, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” with publication date: May 17, 2018 was also an interesting one.

Cardinal Capital Management Llc, which manages about $1.96 billion and $2.69 billion US Long portfolio, upped its stake in Rsp Permian Inc (NYSE:RSPP) by 45,085 shares to 460,448 shares, valued at $21.59M in 2018Q1, according to the filing. It also increased its holding in Mb Financial Inc New (NASDAQ:MBFI) by 130,452 shares in the quarter, for a total of 2.22 million shares, and has risen its stake in Starwood Ppty Tr Inc (NYSE:STWD).

Investors sentiment decreased to 1.06 in 2018 Q1. Its down 0.19, from 1.25 in 2017Q4. It dropped, as 16 investors sold LGND shares while 109 reduced holdings. 52 funds opened positions while 80 raised stakes. 22.56 million shares or 0.54% less from 22.68 million shares in 2017Q4 were reported. Piedmont Inv Advisors has 0.02% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 4,511 shares. First Personal Fin stated it has 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Employees Retirement Association Of Colorado reported 4,180 shares. Two Sigma Limited Liability Com holds 0% or 3,175 shares in its portfolio. Keybank National Association Oh reported 2,605 shares or 0% of all its holdings. Pinebridge Invs LP has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Elk Creek Prtnrs Limited Liability Corporation invested 0.98% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Cornerstone Capital stated it has 2.05% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Congress Asset Communication Ma reported 0.05% stake. Tradewinds Mgmt Ltd reported 119 shares. Bluemountain Mgmt Ltd has 3,259 shares. Verity Asset Inc holds 2,737 shares or 0.41% of its portfolio. Columbia Prtn L L C Investment Mgmt reported 2,887 shares or 0.06% of all its holdings. Lyon Street Capital Limited Liability Company invested in 2.19% or 41,133 shares. Pitcairn stated it has 2,484 shares.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 29 analyst reports since September 3, 2015 according to SRatingsIntel. On Wednesday, October 11 the stock rating was maintained by Roth Capital with “Buy”. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Buy” rating by TH Capital on Thursday, November 19. The firm earned “Hold” rating on Tuesday, August 8 by Deutsche Bank. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, October 5. As per Wednesday, November 15, the company rating was maintained by Craig Hallum. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Buy” rating given on Monday, February 26 by Roth Capital. The rating was maintained by TH Capital on Wednesday, September 30 with “Buy”. As per Friday, December 18, the company rating was maintained by TH Capital. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Buy” rating given on Thursday, February 22 by Stephens. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Sell” rating given on Monday, November 20 by Deutsche Bank.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>